German study tracks new brain tumor Drug's impact on daily life
NCT ID NCT07240662
Summary
This study aims to learn how the drug vorasidenib affects the daily lives and well-being of adults with a specific type of slow-growing brain tumor (IDH-mutant grade 2 glioma) in real-world German clinics. It will follow 150 patients who are already prescribed this drug after surgery to see how it impacts their quality of life, seizure frequency, and disease progression. The main goal is to understand the patient experience, not to test if the drug works, as it is already an approved treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg
RECRUITINGHeidelberg, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.